Special Report - June 2008
This special edition of Envisage is intended to provide an in-depth assessment of the changing landscape of drug development and offer some insight into how medicines may be developed in the future.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- Asian Migration
-
Access to patients, lower costs and increased efficiencies are leading to an explosion in the amount of clinical research being conducted in Asia.
- Joining Forces
-
Global partnerships enable big pharma to streamline drug development and refocus their efforts on core competencies.
Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.